Annual CFO
-$78.33 M
-$10.76 M-15.92%
December 31, 2023
Summary
- As of February 26, 2025, ACRS annual cash flow from operations is -$78.33 million, with the most recent change of -$10.76 million (-15.92%) on December 31, 2023.
- During the last 3 years, ACRS annual CFO has fallen by -$39.69 million (-102.74%).
- ACRS annual CFO is now -1491.97% below its all-time high of -$4.92 million, reached on December 31, 2013.
Performance
ACRS Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
$22.00 M
+$34.32 M+278.54%
September 30, 2024
Summary
- As of February 26, 2025, ACRS quarterly cash flow from operations is $22.00 million, with the most recent change of +$34.32 million (+278.54%) on September 30, 2024.
- Over the past year, ACRS quarterly CFO has increased by +$46.56 million (+189.59%).
- ACRS quarterly CFO is now at all-time high.
Performance
ACRS Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$17.90 M
+$46.56 M+72.23%
September 30, 2024
Summary
- As of February 26, 2025, ACRS TTM cash flow from operations is -$17.90 million, with the most recent change of +$46.56 million (+72.23%) on September 30, 2024.
- Over the past year, ACRS TTM CFO has increased by +$72.78 million (+80.26%).
- ACRS TTM CFO is now -538.76% below its all-time high of -$2.80 million, reached on March 31, 2015.
Performance
ACRS TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
ACRS Cash From Operations Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -15.9% | +189.6% | +80.3% |
3 y3 years | -102.7% | +307.4% | +59.2% |
5 y5 years | +22.3% | +194.2% | +75.1% |
ACRS Cash From Operations Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -50.2% | at low | at high | +183.5% | at high | +80.3% |
5 y | 5-year | -102.7% | +18.8% | at high | +183.5% | at high | +81.4% |
alltime | all time | -1492.0% | +22.3% | at high | +170.3% | -538.8% | +83.8% |
Aclaris Therapeutics Cash From Operations History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2024 | - | $22.00 M(-278.5%) | -$17.90 M(-72.2%) |
Jun 2024 | - | -$12.32 M(-40.8%) | -$64.45 M(-11.4%) |
Mar 2024 | - | -$20.82 M(+207.9%) | -$72.79 M(-7.1%) |
Dec 2023 | -$78.33 M(+15.9%) | -$6.76 M(-72.5%) | -$78.33 M(-13.6%) |
Sep 2023 | - | -$24.56 M(+18.9%) | -$90.68 M(+22.6%) |
Jun 2023 | - | -$20.65 M(-21.6%) | -$73.94 M(+1.4%) |
Mar 2023 | - | -$26.35 M(+37.9%) | -$72.95 M(+8.0%) |
Dec 2022 | -$67.57 M(+29.6%) | -$19.11 M(+144.5%) | -$67.57 M(+3.1%) |
Sep 2022 | - | -$7.82 M(-60.3%) | -$65.53 M(-4.1%) |
Jun 2022 | - | -$19.67 M(-6.2%) | -$68.32 M(+12.2%) |
Mar 2022 | - | -$20.97 M(+22.8%) | -$60.87 M(+16.8%) |
Dec 2021 | -$52.13 M(+34.9%) | -$17.07 M(+61.0%) | -$52.13 M(+18.7%) |
Sep 2021 | - | -$10.61 M(-13.2%) | -$43.92 M(-3.4%) |
Jun 2021 | - | -$12.22 M(-0.1%) | -$45.46 M(+3.2%) |
Mar 2021 | - | -$12.23 M(+38.1%) | -$44.06 M(+14.0%) |
Dec 2020 | -$38.63 M(-59.9%) | -$8.86 M(-27.1%) | -$38.63 M(-23.0%) |
Sep 2020 | - | -$12.15 M(+12.3%) | -$50.17 M(-18.3%) |
Jun 2020 | - | -$10.82 M(+59.0%) | -$61.38 M(-14.7%) |
Mar 2020 | - | -$6.80 M(-66.6%) | -$71.93 M(-25.4%) |
Dec 2019 | -$96.44 M | -$20.39 M(-12.7%) | -$96.44 M(-6.6%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2019 | - | -$23.36 M(+9.3%) | -$103.30 M(-5.9%) |
Jun 2019 | - | -$21.38 M(-31.7%) | -$109.80 M(-0.4%) |
Mar 2019 | - | -$31.32 M(+14.9%) | -$110.26 M(+9.4%) |
Dec 2018 | -$100.81 M(+84.4%) | -$27.25 M(-8.7%) | -$100.81 M(+9.8%) |
Sep 2018 | - | -$29.86 M(+36.8%) | -$91.77 M(+21.3%) |
Jun 2018 | - | -$21.83 M(-0.2%) | -$75.63 M(+18.4%) |
Mar 2018 | - | -$21.87 M(+20.1%) | -$63.88 M(+16.9%) |
Dec 2017 | -$54.66 M(+58.0%) | -$18.21 M(+32.8%) | -$54.66 M(+22.8%) |
Sep 2017 | - | -$13.71 M(+36.1%) | -$44.52 M(+9.4%) |
Jun 2017 | - | -$10.08 M(-20.4%) | -$40.72 M(+0.9%) |
Mar 2017 | - | -$12.66 M(+56.8%) | -$40.37 M(+16.7%) |
Dec 2016 | -$34.60 M(+69.9%) | -$8.07 M(-18.5%) | -$34.60 M(+12.8%) |
Sep 2016 | - | -$9.90 M(+1.8%) | -$30.67 M(-2.1%) |
Jun 2016 | - | -$9.73 M(+41.2%) | -$31.33 M(+28.1%) |
Mar 2016 | - | -$6.89 M(+66.6%) | -$24.46 M(+20.1%) |
Dec 2015 | -$20.37 M(+166.7%) | -$4.14 M(-60.9%) | -$20.37 M(+25.5%) |
Sep 2015 | - | -$10.57 M(+269.3%) | -$16.23 M(+186.6%) |
Jun 2015 | - | -$2.86 M(+2.1%) | -$5.66 M(+102.1%) |
Mar 2015 | - | -$2.80 M | -$2.80 M |
Dec 2014 | -$7.64 M(+55.2%) | - | - |
Dec 2013 | -$4.92 M | - | - |
FAQ
- What is Aclaris Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Aclaris Therapeutics?
- What is Aclaris Therapeutics annual CFO year-on-year change?
- What is Aclaris Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Aclaris Therapeutics?
- What is Aclaris Therapeutics quarterly CFO year-on-year change?
- What is Aclaris Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Aclaris Therapeutics?
- What is Aclaris Therapeutics TTM CFO year-on-year change?
What is Aclaris Therapeutics annual cash flow from operations?
The current annual CFO of ACRS is -$78.33 M
What is the all time high annual CFO for Aclaris Therapeutics?
Aclaris Therapeutics all-time high annual cash flow from operations is -$4.92 M
What is Aclaris Therapeutics annual CFO year-on-year change?
Over the past year, ACRS annual cash flow from operations has changed by -$10.76 M (-15.92%)
What is Aclaris Therapeutics quarterly cash flow from operations?
The current quarterly CFO of ACRS is $22.00 M
What is the all time high quarterly CFO for Aclaris Therapeutics?
Aclaris Therapeutics all-time high quarterly cash flow from operations is $22.00 M
What is Aclaris Therapeutics quarterly CFO year-on-year change?
Over the past year, ACRS quarterly cash flow from operations has changed by +$46.56 M (+189.59%)
What is Aclaris Therapeutics TTM cash flow from operations?
The current TTM CFO of ACRS is -$17.90 M
What is the all time high TTM CFO for Aclaris Therapeutics?
Aclaris Therapeutics all-time high TTM cash flow from operations is -$2.80 M
What is Aclaris Therapeutics TTM CFO year-on-year change?
Over the past year, ACRS TTM cash flow from operations has changed by +$72.78 M (+80.26%)